UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) |
December 15, 2014 |
NAVIDEA BIOPHARMACEUTICALS, INC. |
(Exact name of registrant as specified in its charter) |
Delaware |
001-35076 |
31-1080091 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
5600 Blazer Parkway, Suite 200, Dublin, Ohio |
43017 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code |
(614) 793-7500 |
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 15, 2014, Macrophage Therapeutics,
a business unit of Navidea Biopharmaceuticals, Inc. (the “Company”), hosted a conference and webinar to present research
data from independent academic collaborators in connection with potential therapeutic applications of its Manocept™ platform
in Kaposi’s Sarcoma and other diseases. The data was summarized in a press release issued by the Company on December 15,
2014. A copy of the Company’s December 15, 2014, press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
The information contained in Item 8.01 of
this Current Report on Form 8-K shall not be treated as “filed” for purposes of the Exchange Act or incorporated by
reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 |
Financial Statements and Exhibits. |
Exhibit |
|
Number |
Exhibit Description |
|
|
99.1 |
Navidea Biopharmaceuticals, Inc. press release dated December 15, 2014, entitled “Data Presented by Independent Academic Collaborators Demonstrate Ability of Novel Manocept™ Immunotherapy to Kill Activated Macrophages from KS Patients.” |
Statements contained or incorporated by
reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the
Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies,
and markets for the Company’s products, are forward-looking statements. The words “believe,” “expect,”
“anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements
that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could
cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited
to, the Company’s continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition,
limited marketing and manufacturing experience, and other risks detailed in the Company’s most recent Annual Report on Form
10-K and other filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Navidea Biopharmaceuticals, Inc. |
|
|
|
|
|
|
Date: December 17, 2014 |
By: |
/s/ Brent L. Larson |
|
|
|
Brent L. Larson, Executive Vice President and
Chief Financial Officer |
|
|
|
Exhibit 99.1
FOR IMMEDIATE RELEASE
Data Presented by Independent Academic
Collaborators Demonstrate
Ability of Novel Manocept™ Immunotherapy to Kill Activated
Macrophages from KS Patients
DUBLIN OHIO, December 15, 2014 -- Macrophage
Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), hosted a conference where data
was presented using Manocept™ platform compound, tilmanocept, that was generated by independent academic collaborators with
expertise in the HIV/AIDS, cancer, tuberculosis (TB), rheumatoid arthritis and cardiovascular
disease therapeutic areas. The technical presentations highlighted tilmanocept’s ability to target activated macrophages
implicated in pathology. Specifically data were presented in:
1. Kaposi’s Sarcoma cells from human
tumor extracts that contain tumor associated macrophages (TAM’s) and are often infected with HIV. Data demonstrated that
a generic anticancer agent that has no direct activity vs. HIV, conjugated to tilmanocept killed the CD-206 positive TAM’s.
2. Tilmanocept labeled with a fluorescent
reporter demonstrated a high degree of co-localization with tuberculosis-associated activated macrophages, which express CD-206,
from TB granulomas extracted from human and primate tissue.
3. Rheumatoid Arthritis (RA) - Data presented
indicated that tilmanocept containing a florescent reporter molecule demonstrates selective localization solely into rheumatoid
affected joints in a whole live animal model of RA.
Michael McGrath, M.D., Ph.D., Professor,
University of California, San Francisco, School of Medicine, presented data from patient tumor extracts that demonstrated highly
selective killing of only the CD206 positive cells, e.g., the tumor associated macrophages. Dr. McGrath discussed ongoing studies
designed to further elucidate the tilmanocept conjugates effects on the tumor cells and its contents. “This is an approach
that would be predicted to effectively target the long-lived HIV reservoirs resistant to all current anti-viral therapies,“
said Dr. McGrath.
Data presented by Frederick O. Cope, Ph.D.,
Senior Vice President and Chief Scientific Officer of Navidea, generated with colleagues Drs. Larry Schlesinger, Thomas Rosol and
Wael Jarjour from The Ohio State University, demonstrated the ability of tilmanocept, conjugated to a generic active agent, to
eliminate tuberculosis from TB-infected macrophages at levels significantly lower than currently clinically required. This suggests
that targeting activated macrophages may improve the therapeutic index of existing narrow therapeutic index drugs. In addition,
it suggests the potential utility of using tilmanocept, linked to other active agent(s), to broadly regulate activated macrophages.
Data presented by Steven Grinspoon, M.D.,
Professor of Medicine at Harvard Medical School highlighted the potential for a targeted agent to activated macrophages in cardiovascular
disease. “Atherogenesis is a macrophage-driven process and strategies to image and target activated macrophages in vulnerable
plaque would be a significant advance in the field. Data presented by the other presenters at this meeting were encouraging, and
suggests that tilmanocept is a promising compound to explore in cardiovascular disease,” said Dr. Grinspoon.
-more-
NAVIDEA BIOPHARMACEUTICALS
Page | 2
Navidea director Michael M. Goldberg, M.D.,
who is leading Navidea’s Macrophage Therapeutics efforts, commented, “the data presented today will shortly be enhanced
by data from ongoing studies to further advance this novel immunotherapy approach. We are in the process of assembling a world
class Scientific Advisory Board that will assist in guiding our research further. We look forward to regularly updating the market
with new developments, potential partnerships and results from our ongoing studies.”
About Macrophage Therapeutics
Macrophage Therapeutics, a newly created
business unit of Navidea Biopharmaceuticals, Inc., is developing new therapeutics based on its proprietary CD206 targeting technology
platform. This will represent a new paradigm in the treatment of disease. Depending on the active agent(s) attached to the Manocept™
backbone as well as other core molecule permutations, it may be possible to approach immunotherapy in a completely novel manner.
This approach has the potential to provide for management and modification of diseases that include the immediate involvement of
macrophages, the biological products of macrophages, or the effective impact of macrophages or their progenitor and/or daughter
elements. Thus, Macrophage Therapeutics’ Manocept platform is designed to specifically address a key element, macrophage
interactions, in the natural progression of clinically significant diseases that impact the lives of patients around the globe.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE
MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical
agents. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform
Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in
this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and
strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and
regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act.
The words “believe,” “expect,” “anticipate,” “estimate,” “project,”
and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that
such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated
results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market
acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital
funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience,
risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report
on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise
any forward-looking statements.
Source: Navidea Biopharmaceuticals, Inc.
Macrophage Therapeutics
Michael M. Goldberg, M.D. 201-608-5218
or
Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
###
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024